This study is currently not recruiting participants.

Preserving Beta-Cell Function with Tocilizumab in New-onset Type 1 Diabetes

Investigational Medication for Preserving Beta Cells in Type 1 Diabetes

Not Recruiting
6 years - 45 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to test whether tocilizumab can help preserve or delay destruction of remaining beta cells in people recently diagnosed with type 1 diabetes.

Detailed description of study

The purpose of this study is to test whether tocilizumab can help protect or delay destruction of remaining beta cells in people recently diagnosed with type 1 diabetes.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: type 1 diabetes
  • Age: 6 years - 45 years
  • Gender: All

This study investigates the potential of an investigational medication to preserve or delay the destruction of remaining beta cells in individuals who have recently been diagnosed with type 1 diabetes. Type 1 diabetes is a condition where the body's immune system attacks and destroys insulin-producing cells in the pancreas, known as beta cells.

Participants in this study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine. The study aims to compare the effects of the investigational medication against the placebo on beta cell preservation.

  • Who can participate: Individuals aged 18 to 45 who have been diagnosed with type 1 diabetes within the past six months may be eligible to participate. Key eligibility factors include a confirmed diagnosis of type 1 diabetes and no prior use of the investigational medication.
  • Study details: Participants will be randomly assigned to receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1409300729

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team